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Significance for public health 
In this pilot study, we propose a multimodal approach to the classification of clot pathologies. 
To our knowledge, our approach is innovative and describes a powerful and promising 




Background: Clot characterization is, to the present days, a multimodal approach: scanning 
the clot by electron microscopy (SEM) is helpful for the visualization of fibrin structure along 
with laboratory parameters such as the clot waveform analysis (CWA) and thrombin 
generation in different settings of clot abnormalities. This study aimed to assess whether the 
coagulative parameters were consistent with the clot images texture acquired by SEM, and 
therefore to propose a more generalist and integrative approach to clots classification. 
Design and Methods: In this pilot study, the examined population consists of eight healthy 
subjects, seven patients affected by Acquired Hemophilia A (AHA) and seven patients treated 
with Vitamin K Antagonists (VKAs), similar for age and gender. We studied the velocity and 
acceleration (1st and 2nd derivative of the aPTT) of clot formation (CWA), the thrombin 
generation, and the clots' scanning by SEM. Images acquired with SEM were then analyzed 
with the MATLAB software with the "Texture Analysis" methods to perform classification. 
Among the various texture parameters, we reported Contrast and Energy. 
Results: Significant differences among healthy subjects, patients with AHA and those treated 
with VKAs were detected for the coagulative parameters. We found no differences between 
VKAs and AHA patients. Contrast and energy highlighted a significant difference among the 
three groups in agreement with the laboratory's parameters. We found no significant 
differences between VKAs and AHA patients. 
Conclusions: The use of SEM, CWA and thrombin generation parameters may be a starting 
point for studies aimed to demonstrate the general characteristics of clot formation in different 
clinical conditions with a multiparametric approach.  
 
Keywords: clot pathologies, scanning electron microscopy (SEM), texture analysis, clot 
waveform analysis (CWA). 
 
Introduction 
Blood coagulation is a conventional defensive system versus bleeding, infections and 
neoplastic cells.1 The outcome is a clot consisting of a fibrin network whose properties are to 
form the hemostatic plug along with platelets on one hand and trap, and so kill, pathogens on 
the other. Blood coagulation activation is triggered by tissue factor (TF), a 47 kDa 
transmembrane glycoprotein that envelopes all blood vessels ready to activate the blood 
coagulation cascade when an injury occurs. However, TF can induce both venous and arterial 
thrombosis since it is expressed by foam cells in the atherosclerotic plaques and monocytes 
after activation by pathogens during sepsis, thus leading to disseminated intravascular 
coagulation. Moreover, cancer cells can release micro-vesicles carrying TF, which can 
provoke venous thromboembolism.2 Fibrin formation comes from thrombin, the final protease 
of blood coagulation activation, which is able to cleave fibrinopeptide A and B from the 
fibrinogen molecule, thus inducing polymerization of fibrin monomers which then lead to 
fibrin I formation. The next step is the thrombin activation of factor XIII which induces fibrin 
cross-link at lysine residues of adjacent monomers and an alpha chain of the opposing ones.3 
The clot is then produced. However, several congenital and acquired diseases can affect fibrin 
formation, so that bleeding occurs. Oral and parental anticoagulants can as well reduce the 
coagulative potential so limiting the thromboembolic risk but increasing the bleeding one. In 
other words, the clot becomes weak in all those conditions.  
Looking at the clot by scanning electron microscopy (SEM) may be useful for the 
visualization of the fibrin structure.4 It has been demonstrated that fibrin structure is 
associated with venous thromboembolism showing the so-called prothrombotic fibrin clot 
phenotype.5 The primary aim of our study was to obtain information on the characteristics of 
the clot texture by SEM imaging to classify different groups of clot abnormalities and to 
evaluate whether they could be correlated with the amount of plasmatic thrombin generation, 
along with the velocity and the acceleration of the clot formation. We focused our attention on 
two groups of patients at risk of major bleeding, i.e., patients affected by acquired 
haemophilia A (AHA), a severe life-threatening haemorrhagic disease induced by 
autoantibodies against the coagulation factor VIII6 and patients treated with oral 
anticoagulants such as anti-vitamin K antagonists (VKAs)7 compared to a healthy subjects 
control group. In addition, this study was also planned to obtain information on the 
characteristics of the clot structure aimed at detecting possible anomalies not shown by the 
laboratory investigation, such as a pro-hemorrhagic fibrin clot phenotype. 
 
Design and Methods 
Patients  
For this first explorative study, we evaluated a total of 22 patients, divided into three groups: 
eight healthy subjects, seven patients affected by AHA and seven patients treated with VKAs, 
similar for age and gender. Patients with AHA were studied as they were admitted to our 
clinical ward of Internal Medicine at the onset of the disease, i.e., when they were bleeding 
(Table 1). Patients treated with VKAs showed an International Normalized Ratio (INR) 
between 2.0 and 4.0 (Table 2). Plasma used for this study was a part left from blood sampling 
from a routine investigation. No further blood sampling was drawn. Patients and healthy 
subjects gave their informed consent. This study was approved by the Independent Ethical 
Committee of the Teaching Hospital of Cagliari (Prot. PG/2021/153). All the procedures 
performed in this study involving human participants were in accordance with the ethical 
standards of the institutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards. 
 
Statistical analysis 
The data are expressed as median and range because they were not normally distributed. A 
non-parametric analysis of variance (Kruskal-Wallis test) and the Dunn post-hoc test was 
used for comparison among and between groups. MedCalc software (version 19.0, Ostend, 
Belgium) was used for statistical analysis. 
 
Clot preparation for Clot Waveform Analysis, Thrombin Generation and SEM scanning 
Blood samples were collected by venous withdrawal using 3 mL vacuum tubes (Venosafe, 
Terumo Italia, Rome, Italy) containing sodium citrate 0.109 M (3.2%). Plasma was obtained 
by centrifuging the tubes at 2020 g for 20 min at 20°C. The plasma of patients and controls 
was distributed into aliquots, which included routine coagulative tests, then immersed in 
liquid nitrogen and stored at -80°C until analysis. They were then thawed in a thermostatic 
bath at 37°C and analyzed for Clot Waveform Analysis and Thrombin Generation.  
For SEM scanning, thromboplastin, i.e. TF, was added to the plasma, that was mixed for 3 
minutes at 37°C. An aliquot of 25 µL of plasma has been added to 50 µL of thromboplastin 
for clot formation. After 15 min, the clot was placed in a physiological saline solution. The 
sample was then processed to make it observable by SEM using the following standard 
protocol: 1) fixation in 4% buffered formalin (pH 7) for 1 hour, 2) multiple washes in PBS 
(Phosphate Buffered Saline), 3) dehydration by multiple steps with increasing concentrations 
of ethanol up to 100%, 4) drying at the critical point, in CO2, 5) mounting on support with 
double-sided tape and 6) deposition of 20 nm gold conductive film with sputter coating 
(Cressington CR10-A). Finally, the samples were observed at SEM (ZEISS SIGMA 300). 
The observation was conducted with an exploration of some particular region of interest (see 
below for technical details), to obtain images expression of morphological characteristics of 
the sample. 
 
Laboratory plasma testing 
Thrombin generation 
Thrombin Generation (TG) was determined in Platelet Poor Plasma (PPP) using the 
Calibrated Automated Thrombogram (CAT) method (Diagnostica Stago, Asnières sur Seine 
France).8 An aliquot of 80 µl of PPP was pipetted into the well of a microtiter plate together 
with 20 µl of PPP-Reagent +/- TM (with and without Thrombomodulin) (Thrombinoscope 
BV, Maastricht, The Netherlands), PPP-Reagent contains a mixture of Tissue Factor (5 pM 
final concentration) and synthetic phospholipids (4 µM final concentration), PPP-Reagent 
with Thrombomodulin contains a mixture of Phospholipids, Tissue Factor and 
Thrombomodulin (in the range of 4–6 nM). The reaction was started with 20 µl of a mixture 
composed of the fluorogenic thrombin substrate (Z-GlyGly-Arg-AMC, Thrombinoscope BV, 
417 µM final concentration) and calcium chloride (15 mM final concentration). The substrate 
was cleaved by the thrombin formed and liberates a fluorophore, which is converted to 
thrombin-equivalent concentrations (nM) using a reference curve. Fluorescence was read in a 
Fluoroscan Ascent® reader (Thermo Fisher Scientific Corporation, Vantaa, Finland), and the 
thrombin generation curves were calculated using the Thrombinoscope Software. Thrombin 
generation curves were plotted, and the endogenous thrombin potential (ETP, the area under 
the curve, nM*min), Peak height (nM), Time to peak (min) and the Velocity index (nM/min) 
were recorded. The ETP is the area under the curve (AUC) representing all the enzymatic 
activity of thrombin when it is activated. Therefore, it is the parameter that properly 
represents the coagulation phase. The Peak height is the maximum amount of thrombin 
activated in the process, while the Time to peak represents the time that it takes to obtain the 
peak of thrombin activity from the moment the coagulation starts. The Velocity Index is the 
slope of the curve from the moment of activation of thrombin to its peak; it represents the 
speed with which the reaction reaches its maximum thrombin activity.   
 
Clot Waveform Analysis 
CWA detects the hidden parameters of a simple coagulative test, such as the activated Partial 
Thromboplastin Time (aPTT). It works by means of an automated coagulometer (ACL TOP 
500 CTS, Werfen-Instrumentation Laboratory, Barcelona, Spain) employing a turbidimetric 
method for clot detection. The parameters examined by CWA were the following: (a) time at 
which maximum velocity of clot formation is reached (1st derivative, expressed as mAbs/s) 
and (b) time at which maximum change in acceleration of clot formation is reached (2nd 
derivative, expressed as mAbs/s2) (Table 3). These parameters of the clot formation can be 
obtained by means of implemented software dedicated to the ACL TOP 500 CTS.9 This 
method has been standardized by an official communication of the Subcommittees of the 
International Society of Thrombosis and Haemostasis (ISTH).10 
 
Images from SEM: scanning and image acquisition 
All the images from the SEM were taken using standard capture parameters. Magnification: 
20.000x - WD (Working Distance): 7.0 mm - Electron High Tension (EHT): 15.00 KV - SE2: 
Secondary electron detector. The images were captured in 2048x1536 pixels. These 
conditions allowed to prevent optical distortions and aberrations leading to a misinterpretation 
of the morphological data, given the considerable variety of samples. Therefore, the care in 
obtaining the images has been concentrated on the homogeneity of the signal, both at the 
origin voltage acceleration and enlargement and in the response signal of the sample, due to 
working distance and brightness and contrast modulations. 
 
Images analysis 
Images acquired were analyzed with the Texture Analysis methods to perform classification. 
Texture definition of an image can be reported as the particular geometric arrangement of 
grey levels of the pixels defined in a local region of the image. It is important to keep in mind 
that texture is a property of a region and not a single pixel in the image. Parameters describing 
the texture of images are calculated by the Grey Level Co-Occurrence Matrix (GLCM) 
methods, and calculation were performed by homemade routine scripts in MATLAB 
environment.11 Texture analysis is used in various contexts, including, for example, the 
processing of medical mammographic images. The Grey Level Co-Occurrence Matrix 
(GLCM) is one of the most widely used statistical analysis examining the spatial distribution 
of pixel grey levels within an image.12,13 Among the various texture parameters, we reported 
here contrast and energy whose detailed meaning is described below.  
Contrast is a quantity correlated with the visual perception of the brightness of details in the 
image. The contrast parameter, calculated in the GLCM approach, returns a measure of the 
intensity of differences between a pixel and its neighbors over the whole image. It has a range 
depending on the size of the GLCM matrix, but the lower contrast value of 0 is for a 
"constant" image.  
 
Formula 1. Contrast calculation formula: Pij is the element i,j of the GLCM matrix. 
Energy is a measure of the structures' uniformity in the image. The energy is high when the 
image has the pixels grey levels distribution very regular and, for this reason, is related to the 
uniformity of the diagnostic image. It has the range [0/1], and it is 1 for a "constant" image.  
 
Formula 2. Energy calculation formula: Pij is the element i,j of the GLCM matrix. Results are 
expressed as arbitrary units.  
 
Results 
Results show a significant difference among the three groups of patients as indicated by 
ANOVA for all parameters examined except time to peak. Dunn's post-hoc test shows a 
significant difference among healthy subjects and both anticoagulated and haemophilic 
patients for the following parameters: 1st, 2nd derivative of the aPTT, ETP, peak and the 
velocity index.  
No statistically significant differences were found between anticoagulated and haemophilic 
patients for all the examined parameters. Only the velocity index was significantly lower in 
AHA patients when compared with both VKAs patients and normal subjects.  
Examples of thrombin generation are depicted in Figure 1 for AHA (1A), VKA treatment 
(1B) and healthy subjects (1C); CWA and clot textures for AHA, VKA treatment and healthy 
subjects are depicted in the Figures 2, 3 and 4. All the results are shown in Table 3.  
When contrast and energy were examined, ANOVA highlighted a significant difference 
between the three groups. In particular, the contrast appeared significantly lower in normal 
subjects than in anticoagulated patients and those with AHA. No significant differences were 
found between anticoagulated and haemophilic patients  
 
Discussion 
Clot morphology was used by Undas to identify hypercoagulability conditions through the Ks 
index and fibrin fiber size.4 Ks index (Darcy's constant) is a measure of the average pores 
between fibrin fibers. It shows the fibrin network density in a plasma-based, hydrostatic 
pressure-driven assay in the presence of thrombin and calcium.14 
In this preliminary study, we decided to use different but simpler methods in order to analyze 
clot formation and morphology in three categories of subjects: normal, anticoagulated patients 
with VKAs, and patients with AHA. In other words, we were interested in the study of low 
coagulative states. Alongside the clot texture, analyzed through MATLAB, we determined 
some other parameters related to thrombin generation and the velocity and acceleration of the 
clot formation (Table 4). The primary aim was to assess whether the different laboratory 
coagulation parameters were consistent with the clot texture. The laboratory results highlight 
that patients treated with VKAs and patients affected by AHA showed highly significant 
differences when compared with normal subjects in terms of thrombin generation and velocity 
and acceleration of clot formation. Moreover, peak, time to peak and velocity index were 
lower in patients with AHA in comparison with the anticoagulated patients. These findings 
deserve a dedicated comment. Although the results were significantly different only for the 
velocity index, it explains what is typical of AHA, which is a disease characterized by a low 
level of factor VIII, which has a crucial role in the acceleration of the blood coagulation 
cascade. The physiological behavior of factor VIII explains why in our patients, ETP is not 
different from healthy subjects because the amount of thrombin is normal in haemophilia, but 
the critical point is the time to reach an optimal thrombin production. That delay may be 
critical since the haemostatic system requires an immediate and very rapid reaction if even a 
minimal vascular injury occurs.15 Our results confirm that delay in thrombin generation. Both 
coagulative tests, i.e. thrombin generation and derivatives, appear to be coherent with the clot 
texture results, thus showing a significantly weaker clot morphology as demonstrated by the 
values of contrast and energy. Looking more deeply at the results, we see that both clot 
texture and coagulative parameters were more compromised in patients with AHA than those 
with VKAs. These findings, although not significant due to the small number of patients 
examined, were expected because patients with AHA had at the onset a severe haemorrhagic 
syndrome, typical of the disease.16 No bleeding was recorded in patients treated with VKAs 
who were not in an overdose state. However, both factor VIII level and an optimal 
anticoagulation range are not predictive of no bleeding in these subjects since they can bleed 
regardless of laboratory tests values.17,18 Clot morphology studied at SEM can therefore help 
in examining particular patients who bleed despite their factor VIII value being, for example, 
above 5%, thus defining mild haemophilia and why patients treated with VKA can bleed 
despite optimal anticoagulation. The visualization and determination of clot texture by SEM 
and Texture Analysis could allow to detect additional defects, so explaining the reason of 
bleeding in these subjects. In fact, the morphological examination can highlight areas of 
absence of fibrin fibers, as is evident in Figure 3A. The use of SEM should be therefore 
dedicated only to special and difficult cases for which there is no appropriate explanation for 
bleeding. SEM may have, if well focused, an important role in the evaluation of the single 
patient. The effort made in this work was to demonstrate that a synergy between a blood 
coagulation laboratory and SEM is possible and desirable.  
The limitations of this study are represented by the small sample size and the fact that only a 
few texture parameters resulted statistically significant in our analysis. But this is a pilot study 
realized to acquire important preliminary information about the application of the SEM and 
Texture Analysis to the coagulative pathologic conditions. 
What can we learn from this research experience? The use of SEM seems to be promising in 
working along with the laboratory dedicated to haemostasis. Other clot strength detection 
such as fiber size and organization could further emphasize the potential of SEM in the study 
of hypocoagulability in other clinical conditions such as disseminated intravascular 
coagulation, defects of other clotting factors and, sometimes, unexplained haemorrhagic 
conditions. Other fields of interest are those related to the hypercoagulable states which 
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Figure 1. Examples of thrombin generation of a patient with AHA (A), treatment with VKAs 
(B) and a healthy subject (C).  
 
Figure 2. Examples of CWA and clots texture image of patients with AHA.  
 




Figure 4. Examples of CWA and clots texture image of healthy subject. The absorbance clot 
waveform and first and second derivative waveforms describe the process of clot formation; 
the blue colored trace shows the changes in absorbance; the red-colored curve is the first 
derivative of the absorbance (coagulation velocity); the light blue colored curve is the second 
derivative of the absorbance (coagulation acceleration). 
Table 1. Characteristic of the patients affected by Acquired Haemophilia A. All the patients 
showed major bleeding at the admission to the clinical ward.  
 





F 81 86.5 2.85 0.7 48 
F 52 51.9 1.71 4.3 38.4 
F 47 66.3 2.19 3.5 40 
M 75 74.9 2.47 5.9 54 
F 61 106.3 3.51 0.0 147 
F 76 62.5 2.06 4.5 22.4 
M 90 112.7 3.72 0.1 41.6 
 
 
Table 2. Clinical characteristics of the patients treated with VKA. 
Patients treated with VKA Sex Years 
Ischemic heart disease and intraventricular thrombosis M 52 
Antiphospholipid antibody syndrome F 77 
Mechanical aortic valve replacement F 42 
DVT lower limbs M 86 
Atrial fibrillation with dilative ischemic heart disease M 52 
Atrial fibrillation with cerebral embolic stroke F 69 
Atrial fibrillation F 90 
 
 
Table 3. Kruskal Wallis test and post-hoc analysis of derivatives of aPTT (1st and 2nd 
derivative) and parameters of the thrombin generation in the three groups examined. Data are 





Table 4. Kruskal-Wallis test and post-hoc analysis of parameters derived from MATLAB. 
Data are expressed as median and range. Rank is referred to the Dunn post-hoc test results. 
a.u., arbitrary units. 
 
